2 - Beyond The 101: Pondering Perplexing Prescribing Issues

Sunday, October 19, 2025

1:30 PM - 3:15 PM US ET

Location: B206

CME Credits: Maximum of 1.75 hours of AMA PRA Category 1 Credit™
MOC Credits: Maximum of 1.75 hours of MOC Credit
CNE Credits: Maximum of 1.75 hours of ANCC Credit
ACPE Credits: ACPE 1.75 knowledge-based contact hours of pharmacy CE
ACPE Number: JA0007082-9999-24-002-L01-P
PACE Credits: Maximum of 2 of PACE contact hours
CE Broker: Maximum of 2 CE broker credit hours

Moderator(s)

Lisa Dumkow, Pharm D., BCIDP (she/her/hers)

Antimicrobial Stewardship Clinical Pharmacist
Trinity Health Grand Rapids
Grand Rapids, MI, United States
Emily Spivak, MD, MHS (she/her/hers)

Professor of Medicine
Internal Medicine, Division of Infectious Diseases
University of Utah School of Medicine
Salt Lake City, UT, United States

Faculty(s)

Cynthia Nguyen, PharmD

Clinical Pharmacy Specialist, Infectious Diseases
University of Chicago Medicine
Chicago, IL, United States
Kyle Molina, Pharm.D.

Infectious Diseases Clinical Pharmacist
Scripps Health
Fallbrook, CA, United States
Pranita Tamma, MD, MHS

Associate Professor
Johns Hopkins University School of Medicine
Baltimore, Maryland, United States

Disclosure(s):

Lisa E. Dumkow, Pharm D., BCIDP: No financial relationships to disclose.

Emily S. Spivak, MD, MHS: No financial relationships to disclose.

Cynthia T. Nguyen, PharmD: No financial relationships to disclose.

Kyle C. Molina, Pharm.D.: Melinta Therapuetics: Advisor/Consultant, Grant/Research Support; Merck, Sharpe & Dohme: Advisor/Consultant, Grant/Research Support; Shionogi: Advisor/Consultant

Pranita Tamma, MD, MHS: No financial relationships to disclose.

Learning Objectives:

At the conclusion of this session, participants will be able to:

evaluate patient, disease, and antibiotic considerations related to the use of oral beta-lactams for severe gram-positive infections;
discuss effective dosing strategies to optimize the use of long-acting lipoglycopeptides;
Compose an overview for current CLSI criteria for interpreting susceptibility to oral cephalosporins for Enterobacterales infections;
review data on the use of ceftriaxone susceptibility as a surrogate for susceptibility to oral third generation cephalosporins.

Presentations:

1:30 PM - 2:05 PM US ET

Oral Beta-Lactams for Severe Gram-Positive Infections – Ready for Prime Time?
Speaker: Cynthia T. Nguyen, PharmD – University of Chicago Medicine
2:05 PM - 2:40 PM US ET

Is There an Optimal Dosing Strategy for Dalbavancin and Oritavancin in Deep-Seated Infections?
Speaker: Kyle C. Molina, Pharm.D. – Scripps Health
2:40 PM - 3:15 PM US ET

Can We Use Ceftriaxone Susceptibility to Interpret Susceptibility to Third-Generation Oral Cephalosporins?
Speaker: Pranita Tamma, MD, MHS – Johns Hopkins University School of Medicine